HIV- infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: ) approved diagnostic tests, or ) the referring physician's written record that HIV infection was documented, with supporting information on the participants relevant medical history and/or current management of HIV infection
HIV plasma HIV- ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays (limit of detection: ) within  weeks prior to registration
HIV positive; documentation of HIV- infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider;\r\n* HIV- RNA detection by a licensed HIV- RNA assay demonstrating >  RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV- western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A licensed assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:\r\n* There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD+ T-cell count or B-cell lymphoma\r\n* In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma\r\n* Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed\r\n* Zidovudine is not allowed\r\n* Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed\r\n* Patients with multi-drug resistant HIV are not eligible
HIV infection.
HIV- infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV- antigen or plasma HIV- ribonucleic acid (RNA) viral load > , copies/mL\r\n* NOTE: the term \licensed\ refers to a United States (U.S.) Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally\r\n* WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV- RNA viral load
HIV- infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: ) approved diagnostic tests, or ) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection
HIV infection
EXCLUSION - TREATMENT: Active infection with HIV or HTLV
Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic tests
Know HIV virus infection
DONOR: Infection with HIV
Patients with documented immunodeficiency such as HIV infection.
Multidrug resistant HIV not amenable to long-term suppression based on either or both:\r\n* Clinical history of poor adherence to multiple antiretroviral drugs deemed sufficient to render effective HIV control unattainable\r\n* HIV mutational analysis (genotyping and/or phenotyping) that reveals high-level resistance such that a combination regimen comprised of agents from at least two drug classes cannot be devised to suppress HIV long-term\r\n* Refusal to adhere to HAART
TREATMENT WITH SJCAR: History of HIV infection
HIV infection
Human immunodeficiency virus (HIV) infected patients (if HIV positive)\r\n* HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:\r\n** No history of acquired immune deficiency syndrome (AIDS) defining illness other than a historic CD+ T-cell nadir < /mm^\r\n** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:\r\n*** The CD+ T-cell counts were generally in excess of /mm^\r\n*** The HIV viral loads were less than  copies/ml if on anti-HIV therapy\r\n*** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms\r\n*** Zidovudine is not allowed as part of the anti-HIV therapy
HIV-positive; documentation of HIV- infection by means of any one of the following: \r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider\r\n* Documentation of receipt of antiretroviral therapy (ART) (at least two different medications) by a licensed health care provider (documentation may be a record of an ART prescription in the participants medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participants name)\r\n* HIV- ribonucleic acid (RNA) detection by a licensed HIV- RNA assay demonstrating >  RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV- Western blot confirmation or HIV rapid multispot antibody differentiation assay\r\nNOTE: A licensed assay refers to a United States (U.S.) Federal Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
Has active human immunodeficiency virus (HIV) infection (as manifested by presence of HIV / antibodies and/or positive HIV enzyme-linked immunosorbent assay [ELISA]/western blot assays)
HIV positive; documentation of HIV- infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of ART (at least three different medications) by a licensed health care provider (documentation may be a record of an antiretroviral therapy (ART) prescription in the participants medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participants name);\r\n* HIV- ribonucleic acid (RNA) detection by a licensed HIV- RNA assay demonstrating >  RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV- western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: a licensed assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational food drug (IND) studies
Any HIV status
Willing to have documentation of HIV status
PART : History of HIV infection
HAPLOIDENTICAL RELATED DONOR: HIV infection
Any HIV status
No uncontrolled bacterial, viral, or fungal infection (infection is permitted if there is evidence of response to medication)\r\n* Note: human immunodeficiency virus (HIV)-infected patients are potentially eligible; eligibility of HIV-infected patients will be determined on a case-by-case basis
HIV infection
HAPLOIDENTICAL DONOR: HIV infection
History of HIV infection.
Evidence of active HepB, HepC, or HIV infection
Known human immunodeficiency virus (HIV)- infection status, as documented by any nationally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by approved test at each study site; United States (U.S.) participants only: alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either:\r\n* Approved diagnostic tests, or\r\n* The referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n** Participants enrolled outside the U.S. must have a confirmatory diagnostic test sequence as appropriate per national standards, detailed as above, performed regardless of prior documented HIV status; for HIV-negative participants, testing must be performed no more than  month prior to study enrollment; NOTE: the term licensed refers to a U.S. Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme/chemiluminescence immunoassay (E/CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV- ribonucleic acid (RNA) viral load
HIV seropositive at or before the time of lymphoma diagnosis; all HIV positive patients are eligible regardless of HIV viral load or antiviral therapy (ART) status; all patients on study will receive ART as per standard guidelines
Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; CD+ count > /ul; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load <  copies HIV RNA/mL; no history of acquired immunodeficiency syndrome (AIDS)-defining conditions; no zidovudine or stavudine are allowed owing to overlapping toxicity with chemotherapy
Documentation of HIV infection at any time prior to study entry; documentation may be molecular (detectable viral ribonucleic acid [RNA] by polymerase chain reaction [PCR]), serologic (positive enzyme-linked immunosorbent assay [ELISA] and positive Western blot), or other federally approved licensed HIV test; prior documentation of HIV seropositivity is acceptable
HIV infection
Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No evidence of co-infection with hepatitis B or C\r\n* CD+ cell count >= /mm^\r\n* No evidence of resistant strains of HIV
HIV infection
Patients who are HIV positive with a detectable viral load >  copies/ml on adequate retroviral therapy must be evaluated for HIV drug resistance test (HIV- genotype); these patients may be enrolled only after discussion with the principal investigator (PI) and the infectious disease team
Subjects with HIV infection.
HIV.
Subjects with documentation of confirmed HIV- infection (i.e. HIV-positive), and a hematologic malignancy who meets all other eligibility requirements must:
Untreatable HIV infection due to multidrug ARV resistance. Subjects with a detectable or standard viral load >  copies/mL should be evaluated with an HIV drug resistance test (HIV- genotype). The results should be included as part of the ARV review (described in Appendix D).
Known history of HIV infection. Testing for HIV status is not necessary unless clinically indicated
HIV or HTLV infection
Subjects with uncontrolled human immunodeficiency virus (HIV) are not eligible; controlled HIV is defined as a CD count > institutional lower limit of normal and no current co-infection; uncontrolled HIV is all other HIV infection; note that patients with controlled infection should be allowed to participate only if they are not receiving prohibited cytochrome P (CYP) interactive medications
Patients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following criteria:\r\n* CD-positive cell count >= lower limit of institutional normal\r\n* HIV viral load < , copies HIV ribonucleic acid (RNA)/mL (if not on anti-HIV therapy) OR <  copies HIV RNA/mL (if on anti-HIV therapy)\r\n* No evidence of hepatitis B or C infection\r\n* No evidence of resistant strains of HIV\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining condition
HIV infection.
Patients with treated HLTV or HIV
Patients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; cluster of differentiation (CD)+ count >= /mm; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load <  copies HIV ribonucleic acid (RNA)/mL; no history of acquired immune deficiency syndrome (AIDS) defining conditions
History of HIV infection.
The patient is seropositive for HIV , HIV , HBV, or HCV
HIV- infection, as documented by a rapid HIV test or any FDA-Approved HIV- Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time prior to study entry. HIV antigen, plasma HIV- RNA, or a secondary antibody test by a method other than rapid HIV and E/CIA is acceptable as an alternative test. Alternatively, if a rapid HIV test or any FDA-Approved HIV- Enzyme or Chemiluminescence Immunoassay (E/CIA) test is not available, two HIV- RNA values ?  copies/mL at least  hours apart performed by any laboratory that has CLIA certification, or its equivalent, may be used to document infection.
Untreatable HIV infection due to multidrug antiretroviral resistance. Patients with a detectable viral load >  copies/ml should be evaluated with an HIV drug resistance test (HIV- genotype). The results should be included as part of the Antiretroviral Review (described in Appendix D). This Review Committee will make the final determination as to whether HIV viremia could potentially be suppressed with alternate antiretroviral therapy. .
HIV infection
Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunocompromise, including a positive HIV test result (enzyme-linked immunosorbent assay [ELISA] and western blot)
HIV infection
History of HIV positivity by (ELISA or Western blot)
Human immunodeficiency virus (HIV) infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
HIV infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
DONOR: Infection with HIV
HIV infection (due to increased risk of severe infection and unknown interaction of moxetumomab pasudotox with antiretroviral drugs)
Evidence of HIV infection
Serologic documentation of HIV infection by any of the Food and Drug Administration (FDA)-approved tests; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior enzyme-linked immunosorbent assay (ELISA) and Western blot, or other approved diagnostic tests
Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic tests
Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic tests
Documentation of HIV status; if participant is HIV positive, HIV- infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA] test kit, and confirmed by Western blot or other approved test, or HIV rapid multispot antibody differentiation assay); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: ) approved diagnostic tests, or ) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n* If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within  weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subjects HIV status
HIV Positive* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within  months before screening or at screening
Patients with HIV
HIV infection; patients should provide consent for HIV testing according to the institutions standard practice
History of HIV infection.
Kown history of HIV.
HIV- infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV- antigen, plasma HIV- ribonucleic acid (RNA) viral load; NOTE: The term licensed refers to a U.S Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV- RNA viral load
HIV infection
Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western Blot, or any other federally approved licensed HIV test; a positive HIV viral load prior to study entry will also be permitted
History of HIV disease and/or treatment with anti-HIV agents.
Serologic evidence of HIV
Standard blood tests that are positive for HIV infection
A positive HIV test result (enzyme-linked immunosorbent assay [ELISA] and Western blot) or history of known HIV; an HIV test will not be required; however, previous medical history will be reviewed
HIV- infection, as documented by a rapid HIV- test or any Food and Drug Administration (FDA)-approved HIV- enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry; alternatively, two HIV- RNA values >  copies/mL at least  hours apart performed by any laboratory that has Clinical Laboratory Improvement Amendments (CLIA) certification, or its equivalent may be used to document infection
HIV positive; documentation of HIV- infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participants medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participants name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the -agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV- ribonucleic acid (RNA) detection by a licensed HIV- RNA assay demonstrating >  RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV- western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n** NOTE: A licensed assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
HIV positive; documentation of HIV- infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participants medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participants name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the -agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV- ribonucleic acid (RNA) detection by a licensed HIV- RNA assay demonstrating >  RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV- western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A licensed assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies
HIV- infection, documented by one of the following any time prior to study entry:\r\n* Any licensed rapid HIV test\r\n* HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit; and confirmed by one of the following:\r\n* Licensed western blot\r\n* Second antibody test by a method other than the initial rapid HIV and/or E/CIA\r\n* HIV- antigen\r\n* Plasma HIV- RNA viral load\r\n* Documentation of receipt of antiretroviral therapy\r\n* Note: the term licensed refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV- RNA viral load
HIV- infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (enzyme linked immunosorbent assay [ELISA], Western blot or other approved test); alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests; if the participants HIV status is documented by an outside physician, the protocol team strongly recommends obtaining a copy of the HIV laboratory reports from this physician; all confirmatory tests and the physicians note must be on file before the participant is enrolled; in the rare circumstance where only an outside physicians note with no supporting laboratory documentation is available, the local site should have additional tests performed to verify the participants HIV status; one of the following additional tests should be performed:\r\n* A rapid HIV test\r\n* ELISA and Western blot\r\n* Chemiluminescence immunoassay and Western blot\r\n* HIV ribonucleic acid (RNA) >  copies/mL\r\n* HIV antigen test
Any HIV status
